PSDV - pSivida Limited Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited

PSDV 1.220

+14.0%

Mar 29 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	6/14/2011 7:01:41 PM
	of 421

Latanoprost = $1.6 billion sales . Latanoprost (pronounced la-TA-noe-prost) ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension by reducing intraocular pressure. . It is a prostaglandin analogue (more specifically an analogue of Prostaglandin F2a[1]) that works by increasing the outflow of aqueous fluid from the eyes (through the uvealsclearal tract).[2] . It is also known by the brand name of Xalatan manufactured by Pfizer. Annual sales are approximately $1.6 billion. . The patent for latanoprost expired in March 2011, and at least one generic version (manufactured by Mylan Inc.) is now widely available in the U.S. Latanoprost was developed by Dr. Carl B. Camras and his research adviser Dr. László Z. Bitó at Columbia University in 1996.[3] . en.wikipedia.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next